Background Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was
shown to have efficacy in patients with advanced RET fusion–positive non–small-cell lung …

PURPOSE Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase
inhibitor, is currently approved for the treatment of patients with RET fusion–positive non …

Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …

Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in
non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have …

Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically
meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment …

Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective
RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung …

Background Selpercatinib is a first-in-class, highly selective RET kinase inhibitor with CNS
activity that has shown efficacy in RET fusion-positive lung and thyroid cancers. RET fusions …

Simple Summary Non-small cell lung cancer (NSCLC) remains a significant cause of death
worldwide, despite the significant progresses to date. Multiple molecular alterations have …

Abstract On September 21, 2022, the FDA granted accelerated approval to selpercatinib
(Retevmo, Eli Lilly and Company) for the treatment of adult patients with locally advanced or …

Background RET fusions are present in 1%–2% of non-small cell lung cancer (NSCLC).
Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor …